[ad_1] NEW CLINIC: The executive board of New York City Health + Hospitals voted Thursday to execute a $30 million contract with Gilbane Building Company

[ad_1] Investments in drug research and development are paying dividends while the cost to do so stays flat, a trend that appears to be benefitting

[ad_1] Tarrytown-based Regeneron Pharmaceuticals has struck a $100 million deal with Mammoth Biosciences, a California-based biotechnology company, to develop and commercialize gene editing therapies for